Small Dense LDL: The Particle Size Debate Explained

The clip runs about forty seconds. A confident voice explains that the LDL number on your lab report is “basically meaningless” because what really matters is whether your particles are “big and fluffy” or “small and dense.” By the end, the comments are full of people asking which test to order and whether their doctor has been lying to them. As of late 2025, searches for small dense LDL have climbed alongside those videos, helped by the fact that several commercial laboratories now list a direct small dense LDL cholesterol assay on their routine menus.

The frustrating thing, for anyone who reads the actual studies, is that the clip is partly right. Particle size is real, and the smaller particles do behave differently inside an artery. The clip is also deeply wrong about what follows from that, because the size story has been tested against the particle-count story for two decades, and size keeps losing.

This piece walks through what small dense LDL is, how it forms, what the evidence can and cannot show, and why the quietly unglamorous number called apoB may deserve more of your attention than any particle diameter.

What is LDL (low-density lipoprotein) cholesterol, and what makes some of it small dense LDL?

Cholesterol is a waxy molecule that cannot dissolve in blood. To travel, it rides inside lipoproteins: spherical packages built from fats and proteins. Low-density lipoprotein, or LDL, is the package that delivers cholesterol out to tissues, and it is the one most firmly linked to atherosclerosis, the slow build-up of cholesterol-rich plaque inside artery walls. A standard lipid panel reports LDL cholesterol (LDL-C), which is the total mass of cholesterol carried by all your LDL particles combined.

That single number hides a crowd. LDL particles range from roughly 18 to 25 nanometers across, about one four-thousandth the width of a human hair. Larger particles are stuffed with cholesterol and sit near the top of that range. Smaller ones have given up some cholesterol, so they are more compact and sink further in a density gradient. Laboratories call the compact end of the spectrum small dense LDL, or sdLDL. The cholesterol carried specifically by those particles is written sdLDL-C.

Two people can share an identical LDL-C of 120 mg/dL and have very different particle populations. One might carry mostly large, cholesterol-rich particles, so fewer particles are needed to reach that total. The other might carry many more small, cholesterol-poor particles to add up to the same mass. Researchers have labeled these distributions pattern A (predominantly large) and pattern B (predominantly small) since the 1980s.

One more fact anchors everything that follows. Every LDL particle, large or small, carries exactly one molecule of a protein called apolipoprotein B, or apoB. Measuring apoB therefore counts particles directly, whatever their size. Keep three terms separate as you read: LDL-C is cholesterol mass, apoB or LDL-P is particle number, and small dense LDL is the subset of particles at the compact end.

What changed recently in the small dense LDL conversation?

The science is not new, but three developments have pushed it back into public view. The first is laboratory access. For most of its history, small dense LDL could only be measured in research settings using slow separation techniques. Over the past decade an automated chemical assay for sdLDL-C has moved onto standard analyzers, which means an ordinary clinic can now add it to a blood draw. A test that is easy to order is a test that gets talked about.

The second is the maturing of large cohort data. The Atherosclerosis Risk in Communities (ARIC) analysis published in 2014 followed more than 11,000 adults for about 11 years and found that higher sdLDL-C predicted coronary heart disease even among people whose standard LDL-C was in a range considered low risk. That paper is still the one most often quoted in favor of measuring the small particles, and it is one of the references for this article.

The third is a guideline shift toward counting particles. The 2018 American cholesterol guideline listed an elevated apoB as a “risk-enhancing factor” that can tip a borderline decision about treatment, and several professional societies in the United States and Europe now describe apoB as an acceptable alternative to LDL-C for tracking risk. None of them recommends routine particle size testing.

Social media compressed all of this into a simpler, more shareable claim: that size, not amount, is what matters. The sections below pull those two ideas apart, because the evidence treats them very differently.

How do small dense LDL particles form in the body?

Small dense LDL is not a separate product the liver manufactures on purpose. It is what happens to an ordinary LDL particle when it circulates in a bloodstream rich in triglycerides, the fat molecules that store energy and rise after meals or with excess calories.

The chain begins with very-low-density lipoprotein, or VLDL, the triglyceride-heavy particle the liver releases to deliver fat to muscle and adipose tissue. As enzymes strip triglyceride from VLDL, it shrinks into LDL. Normally that LDL stays relatively large and cholesterol-rich.

When triglyceride levels are high, a protein called cholesteryl ester transfer protein (CETP) acts like a swap meet. It moves triglyceride from VLDL into LDL and takes cholesterol out of LDL in exchange. The LDL particle is now carrying a load it was not designed for. A second enzyme, hepatic lipase, then chews the triglyceride out of that LDL. What remains is a particle that has lost both cholesterol and triglyceride: smaller, denser, and chemically a little different on its surface.

This explains why fasting triglycerides are the strongest everyday predictor of particle pattern. Studies using gradient gel separation have repeatedly found that pattern B becomes common once triglycerides sit above roughly 130–150 mg/dL, and becomes rare when they fall below about 70 mg/dL. Insulin resistance, the condition in which cells respond sluggishly to insulin so the liver pours out more VLDL, drives the whole cascade. That is why small dense LDL travels with abdominal weight gain, prediabetes and type 2 diabetes, and why it tends to shrink when those conditions improve.

Why might small dense LDL be more damaging to arteries?

Laboratory and animal work suggests at least four reasons the compact particles could do more harm per particle. Each is biologically plausible; none has been shown in humans to matter independently of how many particles are present.

First, small dense LDL binds less tightly to the LDL receptor, the docking site on liver cells that pulls LDL out of circulation. Weaker binding means a longer stay in the blood, which has been estimated in tracer studies at several days versus roughly two for larger LDL. More time circulating means more opportunities to slip into an artery wall.

Second, smaller particles pass more easily through the endothelium, the single-cell lining of blood vessels. Once inside, they stick more firmly to proteoglycans, the sugar-protein mesh of the artery wall, partly because their apoB protein is folded differently on a smaller surface.

Third, small dense LDL oxidizes faster. Its surface carries fewer protective antioxidants and more of the fatty acids that react readily with oxygen. Oxidized LDL is the form that immune cells called macrophages swallow in bulk, turning into the foam cells that form the fatty core of plaque.

Fourth, the particles tend to carry more of certain enzymes and modified fats that promote inflammation within the vessel wall.

Here is the honest caveat. These mechanisms were worked out largely in cell cultures and animals. In people, small dense LDL almost always appears together with high triglycerides, low HDL cholesterol, insulin resistance and a high particle count. Disentangling the particle’s own contribution from the company it keeps is exactly what the human cohort studies tried to do, and their answer is the heart of the debate.

What the evidence actually says about small dense LDL and heart risk

It helps to grade the evidence the way a guideline committee would: randomised trials at the top, large observational cohorts in the middle, mechanisms and expert opinion below.

Randomised trials: none for particle size. No trial has ever assigned people to a strategy of measuring and shrinking small dense LDL and then counted heart attacks. The outcome trials we have tested drugs that lower LDL-C and apoB. Those trials show, consistently, that each reduction in LDL-C of about 39 mg/dL (1 mmol/L) cuts major vascular events by roughly a fifth, regardless of which particle sizes happened to fall.

Observational cohorts: a real but shrinking signal. In ARIC, people in the highest quarter of sdLDL-C had roughly 50% more coronary events than those in the lowest quarter over about 11 years, after adjusting for age, sex and race. Other cohorts in Quebec, Framingham and Japan found similar unadjusted associations. The pattern changes when analysts add triglycerides, HDL and especially particle number to the model. In the Women’s Health Study and the Multi-Ethnic Study of Atherosclerosis, small particle size stopped predicting events once particle number was accounted for, and in some analyses larger particles looked slightly worse at equal particle counts, simply because each large particle carries more cholesterol into the wall.

Mechanisms and expert opinion: supportive but not decisive. The biology in the previous section is widely accepted. The most common expert interpretation is that small dense LDL is a marker of a dangerous metabolic state and a marker of high particle number, rather than a target worth chasing on its own.

The sober summary: higher small dense LDL does flag higher risk, the flag is mostly explained by things your standard panel already captures or that apoB captures better, and no trial shows that acting on size itself saves lives.

Does LDL particle number matter more than particle size?

Picture two highways carrying the same tonnage of cargo. One has 100 full trucks; the other has 300 half-empty vans. The tonnage, like LDL-C, is identical. The number of vehicles that can crash into the barrier, like particle number, is three times higher on the second road.

That image captures what the discordance studies found. Discordance is the situation in which LDL-C and particle number point in different directions: a normal LDL-C with a high particle count, or the reverse. When researchers followed thousands of such people, risk tracked the particle count almost every time. People with low LDL-C but many particles had elevated risk; people with high LDL-C but few particles were closer to average. Because small particles are cholesterol-poor, a person with lots of them is, almost by definition, discordant in the dangerous direction.

This is why many lipid specialists argue that the particle size debate is a detour. Small dense LDL matters mainly because it signals that particle number is higher than LDL-C implies. Once you measure particle number directly, through apoB or an NMR LDL particle count, size adds little. In the Multi-Ethnic Study of Atherosclerosis, for example, neither small nor large particle concentration predicted carotid plaque thickness beyond total particle number.

There is a practical payoff. LDL particle number by NMR requires a specialized instrument, and small dense LDL assays are still not standardized across laboratories. ApoB is a cheap, automated, internationally standardized protein measurement that any hospital lab can run, and it captures the same risk information. For most people wondering whether to “get their particles checked,” that single test answers the useful question.

ApoB vs LDL cholesterol: which is more important?

Apolipoprotein B is the structural protein wrapped around every atherogenic particle: each LDL, each VLDL, each intermediate-density particle and each lipoprotein(a). One particle, one apoB. A blood apoB level is therefore a head count of every particle capable of lodging in an artery wall, not just LDL.

For most people, apoB and LDL-C rise and fall together, so the familiar LDL-C number does its job. The two diverge in predictable groups: people with high triglycerides, abdominal obesity, metabolic syndrome or type 2 diabetes, and people whose LDL-C has already been pushed low by treatment. In those settings, LDL-C can read reassuringly while apoB remains elevated, meaning many small, cholesterol-poor particles are still circulating.

Head-to-head comparisons in large pooled analyses consistently find apoB a slightly better predictor of heart attack than LDL-C, and better than non-HDL cholesterol (total cholesterol minus HDL), which is the standard panel’s own attempt at capturing all the atherogenic particles. The advantage is modest at the population level and larger for the individual whose numbers are discordant.

What this means in practice depends on where you are in the world. The 2018 American guideline keeps LDL-C as the primary measure and treats an apoB at or above 130 mg/dL as a risk-enhancing factor. European guidance since 2019 lists apoB as an alternative primary measurement where available. Both agree on the direction of travel: lower is better, and the treatments proven to reduce events lower both numbers.

So which is more important? If you can only have one number and your triglycerides are normal, LDL-C is fine. If your triglycerides are high or your metabolism is insulin-resistant, apoB tells the truer story. Either way, the decision about whether and how to act on it belongs with your clinician, who can weigh it against your whole risk picture.

What is a good LDL particle size, and is it better to have high or low LDL?

People searching for a “good” particle size are usually hoping for a reassuring threshold. Laboratories do report one. On gradient gel electrophoresis, a peak LDL diameter above about 25.5 nanometers is pattern A, below it pattern B. NMR laboratories use their own scales, typically calling particles larger than roughly 20.5 nanometers “large” and reporting the average as a single number. The cut-offs differ by method and are not interchangeable, so a size from one lab cannot be compared with a size from another.

The more useful answer is that a good particle size is one you did not need to measure because your triglycerides are low and your apoB is low. Pattern A with a high particle count is still high risk. Pattern B with a very low particle count, which is rare but does occur, carries less risk than the size alone would suggest.

The companion question, whether high or low LDL is better, has a less ambiguous answer than social media implies. Lower LDL is associated with less cardiovascular disease across every population studied, down to levels well below what most adults achieve without treatment. People born with genetic variants that keep LDL low lifelong have strikingly low rates of coronary disease. Randomised trials lowering LDL to very low levels have not shown harm from the low LDL itself.

The idea that large, cholesterol-rich LDL is harmless is the part the viral clips get wrong. Large particles carry more cholesterol per particle and are perfectly capable of building plaque; people with familial hypercholesterolemia, a genetic condition causing very high LDL from birth, typically have predominantly large particles and still develop early heart disease. Size is a modifier of risk at the margins. Amount, measured as LDL-C or apoB, is the main event.

What does an LDL particle size test involve?

Several laboratory methods can describe your LDL beyond the standard panel, and they do not measure the same thing. Most require nothing more from you than a routine blood draw, often after fasting, since triglycerides shift after meals and triglycerides shape the result.

Method	What it reports	How it works	Practical notes
Standard lipid panel	LDL-C, HDL-C, triglycerides, total cholesterol	Enzymatic chemistry; LDL-C often calculated	Universally available, standardized, basis of all outcome trials
Apolipoprotein B	Number of atherogenic particles	Immunoassay for the apoB protein	Automated, standardized, recommended by several guidelines
Direct sdLDL-C assay	Cholesterol carried in small dense LDL	Chemical precipitation of larger particles, then cholesterol measurement	Now on many lab menus; thresholds vary by lab; no outcome trials
NMR lipoprotein profile	LDL particle number and average size	Nuclear magnetic resonance signal from particle lipids	Needs a specialized analyzer; size cut-offs differ from gel methods
Gradient gel electrophoresis	Peak LDL diameter, pattern A or B	Particles migrate through a gel by size	Original research method; slow, mostly historical
Ion mobility	Particle counts across size ranges	Particles sorted by electrical mobility in gas	Limited availability; research and specialty use

Nuclear magnetic resonance, in plain terms, reads the faint radio signal given off by fats inside each particle when placed in a magnetic field; the signal’s shape reveals particle size and count. The direct sdLDL-C assay instead uses a chemical that clumps the larger particles so they can be removed, leaving the small ones to be measured.

Two cautions apply to all of them. Results from different methods are not interchangeable, and none has a randomised trial showing that treating to a target improves outcomes. Whether any of these tests is worth ordering is a conversation for your clinician, who may conclude that apoB alone answers the question you are really asking.

Who is most likely to have high small dense LDL?

Because the small particles are forged in a triglyceride-rich bloodstream, the people who carry the most of them are the people whose metabolism produces the most triglyceride. The list reads like the definition of metabolic syndrome, the cluster of abdominal weight, raised blood pressure, raised fasting glucose, high triglycerides and low HDL that signals insulin resistance.

Type 2 diabetes is the clearest example. People with diabetes often have an LDL-C that looks unremarkable while their apoB and sdLDL-C run high, which helps explain why standard LDL-C has historically underestimated their cardiovascular risk. Prediabetes and non-alcoholic fatty liver disease, in which fat accumulates in the liver, show the same shift because the liver exports more VLDL.

Genetics plays a substantial role. Twin and family studies suggest that roughly a third to a half of the variation in LDL particle size is inherited, through variants affecting hepatic lipase, CETP and the enzymes that clear triglyceride. The combination of a genetic tendency and a diet or weight that raises triglycerides is what produces the most extreme pattern B profiles. Men more often show pattern B than premenopausal women, a difference that narrows after menopause as triglycerides rise.

Other contributors are well documented in observational data: central weight gain even within a “normal” body mass index, a diet high in refined carbohydrates and added sugar, heavy alcohol intake, physical inactivity, smoking, and kidney disease. Certain medicines, including some used for HIV, some antipsychotics and oral estrogen, raise triglycerides and can nudge the pattern toward smaller particles; anyone concerned about that should raise it with the prescriber rather than adjust anything themselves.

The through-line is simple. If your triglycerides are consistently high and your HDL low, you probably carry a lot of small dense LDL, and you did not need a specialty test to know that your metabolic health deserves attention.

Can diet, exercise and weight change shift small dense LDL?

Yes, and more readily than almost any other lipid measure, because small dense LDL responds to the same levers that move triglycerides. The evidence here comes mainly from short randomised feeding and exercise studies measuring particle size as an outcome, plus observational data; there are no trials showing that shifting size itself prevents heart attacks.

Weight loss is the most reliable lever. Losing even 5–10% of body weight in people with excess abdominal fat typically lowers triglycerides by a fifth or more and shifts the LDL peak toward larger particles. The mechanism is reduced liver fat and less VLDL production, so fewer particles go through the CETP exchange described earlier.

Carbohydrate quality matters more than total carbohydrate for most people. Diets heavy in refined grains, sugary drinks and added sugar push triglycerides up and particles down in size; replacing them with whole grains, legumes, vegetables and fruit does the opposite. Very-low-carbohydrate diets reliably enlarge LDL particles in trials, but they often raise LDL-C and apoB in a subset of people, so particle size can improve while particle number worsens. That trade-off is a good illustration of why size should never be read in isolation.

Aerobic exercise lowers triglycerides and raises HDL with a dose-response relationship; roughly 150 minutes of moderate activity a week, the amount in mainstream heart-health guidance, produces measurable shifts. Resistance training adds a smaller benefit. Replacing saturated fat with unsaturated fats lowers LDL-C and apoB in trials, which is the outcome that matters most, even though saturated fat tends to raise large rather than small particles. Limiting alcohol and quitting smoking both lower triglycerides.

Put together, these are the same habits that cut cardiovascular risk in every guideline. The particle size story simply gives a mechanism for why they work.

How do cholesterol medicines affect small dense LDL?

Medicines that lower cholesterol vary in how they change particle size, and the history of that variation is one of the most instructive chapters in the whole debate. Nothing here is a recommendation; whether any medicine is appropriate, and in what form, is a decision for the prescribing clinician.

Statins, the most studied class, lower LDL-C and apoB by increasing the liver’s LDL receptors. They remove particles of all sizes roughly proportionally, so sdLDL-C falls substantially in absolute terms while the average particle size changes little. Despite leaving the size pattern largely intact, statins reduce heart attacks and strokes in dozens of randomised trials. That alone shows a shift in size is not required for benefit.

Ezetimibe and the PCSK9 inhibitors also lower all LDL subclasses and have reduced cardiovascular events in outcome trials when added to statins. Again, benefit tracked the fall in LDL-C and apoB.

Fibrates and niacin are the mirror image. Both lower triglycerides and shift LDL toward larger particles, often dramatically improving a pattern B profile on paper. Yet in large randomised trials conducted on top of statin therapy, neither reduced cardiovascular events overall, and niacin added side effects. The particles got bigger; the patients did not do better. Omega-3 fatty acid preparations lower triglycerides too, with mixed outcome results across trials.

Medicines that block CETP, the swap protein that shrinks LDL, have had a complicated trial record, with several failing to show benefit and one showing a modest reduction in events in proportion to its effect on apoB.

Taken together, these trials point in one direction. Treatments earned their place by lowering the number of atherogenic particles, not by changing their diameter. Anyone already prescribed a lipid medicine should continue it as directed and bring questions about particle testing to the person who prescribed it.

Common myths about small dense LDL

Myth: “If my LDL particles are large and fluffy, my high LDL doesn’t matter.” Large particles carry more cholesterol each and build plaque efficiently. The genetic condition that produces the earliest heart attacks, familial hypercholesterolemia, is dominated by large particles. High LDL-C or apoB is a risk whatever the size distribution.

Myth: “Standard cholesterol tests are useless; only particle size counts.” Every drug trial that has ever prevented a heart attack used standard LDL-C to judge success. Particle size has never been tested as a treatment target in an outcome trial.

Myth: “Small dense LDL is the real cause of heart disease.” It is one contributor among many, and in cohort studies its independent effect fades once particle number and triglycerides are accounted for. Think of it as a loud symptom of insulin resistance and particle excess rather than the root cause.

Myth: “Saturated fat is fine because it only raises the large particles.” Saturated fat raises LDL-C and apoB in controlled trials, and apoB is the particle count that predicts events. Raising the harmful total while improving the size ratio is not a win.

Myth: “A low-carb diet fixed my particles, so my heart is protected.” Larger particles with a higher apoB, which some people develop on very-low-carbohydrate diets, is a profile that cohort data link to more risk, not less. The size improvement is real; its protective meaning is not established.

Myth: “Statins don’t help because they don’t change particle size.” Statins lower small dense LDL in absolute terms and cut events in randomised trials. The size pattern staying similar is a point against the size hypothesis, not against the medicine.

Myth: “Everyone should get a particle size test.” No major guideline recommends routine particle size testing. Several endorse apoB, which is cheaper, standardized and captures the useful information.

When to see a doctor about small dense LDL and cholesterol

Cholesterol causes no symptoms until it causes a vascular event, so the right time to talk to a clinician is before you feel anything. Mainstream guidance suggests a baseline lipid panel for adults starting around age 20, repeated roughly every 4–6 years if results are normal and risk is low, and more often with age or when risk factors appear. Children with a family history of early heart disease or very high cholesterol may be tested earlier.

Book a routine appointment to discuss lipids, and ask whether apoB testing is worthwhile, if any of the following apply: triglycerides consistently above 150 mg/dL; type 2 diabetes, prediabetes or fatty liver disease; a waist measurement that has grown even while weight stayed stable; a parent or sibling who had a heart attack or stroke before 55 (men) or 65 (women); an LDL-C result above 190 mg/dL at any age; or a lipid medicine whose effect you want to understand better. Bring the actual reports, since units and methods vary.

Seek urgent care, by calling emergency services, for signs that may indicate a heart attack or stroke, which are the events all of this testing exists to prevent: chest pressure, tightness or pain lasting more than a few minutes or coming and going; pain spreading to the arm, jaw, neck or back; sudden shortness of breath, cold sweat, nausea or light-headedness; sudden weakness or numbness on one side of the face or body; sudden confusion, trouble speaking or understanding; sudden loss of vision or balance. Women more often report unusual fatigue, nausea or breathlessness without classic chest pain.

Finally, never stop, skip or adjust a prescribed cholesterol medicine because of something you read about particle size. If a result worries you, the person to interpret it is the clinician who knows your history.

Frequently asked questions

What is a good LDL particle size?

On gradient gel methods, a peak LDL diameter above about 25.5 nanometers is pattern A and considered favorable; NMR laboratories use different scales. Cut-offs are not interchangeable between methods. More importantly, a favorable size does not cancel a high particle count, so clinicians look at apoB or LDL particle number and triglycerides alongside any size result.

What is more important, apoB or LDL?

ApoB is a slightly better predictor of heart attack than LDL cholesterol in pooled studies, and markedly better when the two disagree, which happens with high triglycerides, diabetes or abdominal obesity. For people with normal triglycerides the two track closely and LDL-C works well. Guidelines keep LDL-C as the primary measure in the US and accept apoB as an alternative in Europe.

Is it better to have a high or low LDL?

Lower LDL is better. Across genetic studies, cohorts and randomised trials, lower LDL cholesterol and apoB track with fewer heart attacks and strokes, with no sign of harm from very low levels achieved by treatment. The idea that a high LDL is safe if the particles are large is not supported; large particles carry more cholesterol each and build plaque efficiently.

What is LDL (low-density lipoprotein) cholesterol?

LDL cholesterol is the amount of cholesterol carried inside low-density lipoprotein particles, the packages that deliver cholesterol from the liver to tissues. It is often called “bad” cholesterol because LDL particles can lodge in artery walls and form plaque. A standard lipid panel reports LDL-C as a mass concentration, usually in mg/dL, and it is the measure used in every major cholesterol-lowering outcome trial.

Does an ldl particle size test change treatment?

Rarely, and no guideline recommends it routinely. The treatments proven to prevent heart attacks lower particle number and LDL cholesterol regardless of size, and medicines that mainly enlarge particles did not reduce events in trials. A clinician may order apoB instead when triglycerides are high or diabetes is present; any change in treatment is their decision based on your full risk picture.

What does ldl particle number mean on a lab report?

LDL particle number, often written LDL-P and reported in nmol/L on an NMR profile, is a count of LDL particles rather than the cholesterol they carry. It behaves much like apoB. A high LDL-P with a normal LDL-C means many small, cholesterol-poor particles are circulating, a pattern linked to higher risk than the LDL-C alone would suggest.

Can small dense LDL be high when total cholesterol is normal?

Yes. Because small particles carry little cholesterol each, a person can have normal total and LDL cholesterol while carrying many small dense particles. This discordance is most common in people with high triglycerides, insulin resistance or type 2 diabetes, and it is the main reason some clinicians add apoB to the standard panel in those groups.

How quickly can lifestyle change small dense LDL?

Within weeks to a few months. Particle size follows triglycerides, which respond quickly to weight loss, reduced refined carbohydrate and added sugar, less alcohol and regular aerobic exercise. Short randomised studies show measurable shifts toward larger particles within 6–12 weeks. Whether that shift itself prevents events has not been tested; the same habits lower apoB and risk through better-established routes.

Is small dense LDL genetic?

Partly. Family and twin studies suggest roughly a third to half of the variation in LDL particle size is inherited, through variants affecting hepatic lipase, CETP and triglyceride-clearing enzymes. Genes set the tendency; triglyceride levels, weight and insulin sensitivity determine how strongly it shows. People with a family history of early heart disease should discuss lipid testing with a clinician.

Do statins lower small dense LDL?

Yes. Statins remove LDL particles of all sizes by increasing liver LDL receptors, so the absolute amount of small dense LDL cholesterol falls even though the average particle size changes little. Their proven reduction in heart attacks and strokes comes from lowering particle number and LDL cholesterol. Any question about starting, continuing or changing a statin belongs with the prescribing clinician.

References

• MedlinePlus: LDL: The "Bad" Cholesterol
• Cleveland Clinic: Lipid Panel

This article is for general information only and is not a substitute for professional medical advice. Please consult a qualified doctor about your individual situation.